GlassScriptPhysician profile
Celine A Daily
NPI 1679624092
$508.70
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $106.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $117.13 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $77.36 | 2019-2020 | |
| Novo Nordisk INC | $60.42 | 2019-2020 | |
| Therapeuticsmd, INC. | $59.34 | 2019 | |
| Merck Sharp & Dohme LLC | $43.01 | 2019-2020 | |
| Radius Health, INC. | $35.03 | 2019-2020 | |
| Amgen INC. | $17.63 | 2019 | |
| Celgene Corporation | $16.19 | 2019 | |
| Currax Pharmaceuticals LLC | $14.87 | 2019 | |
| Daiichi Sankyo INC. | $14.49 | 2019 | |
| Avion Pharmaceuticals | $14.35 | 2019 | |
| Hologic Sales and Service, LLC | $14.28 | 2019 | |
| Pfizer INC. | $13.21 | 2019 | |
| Allergan, INC. | $11.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celine Daily listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.